TY  - JOUR
AU  - Kazimir, Aleksandr
AU  - Schwarze, Benedikt
AU  - Lönnecke, Peter
AU  - Jelača, Sanja
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Hey-Hawkins, Evamarie
PY  - 2023
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/6266
AB  - For decades, tamoxifen-based hormone therapy has effectively addressed oestrogen receptor positive (ER+) luminal A breast cancer. Nonetheless, the emergence of tamoxifen resistance required innovative
approaches, leading to hybrid metallodrugs with several therapeutic effects besides the inhibition of oestrogen receptor α (ERα). Drawing inspiration from tamoxifen metabolite structures (4-hydroxytamoxifen
and 4,4′-dihyroxytamoxifen), a phenyl ring was replaced by a bidentate 2,2′-bipyridine donor moiety to give
4-[1,1-bis(4-methoxyphenyl)but-1-en-2-yl]-2,2′-bipyridine (L), enabling coordination of bioactive transition
metal compounds such as copper(II) dichloride, yielding [CuCl(μ-Cl)(L-κ2N,N′)]2 (1). Notably, copper(II)
complex 1 exhibited remarkable activity within the low micromolar concentration range against ER+ human glioblastoma U251, as well as breast carcinomas MDA-MB-361 and MCF-7, surpassing the efficacy of previously reported palladium(II) and platinum(II) dichloride analogs against these cell lines. The pronounced efficacy of complex 1 against triple-negative MDA-MB-231 cells highlights its potential multitherapeutic approach, evident through induction of apoptosis and antioxidant activity. This study evaluates the potential of copper–tamoxifen hybrid complex 1 as a potent therapeutic candidate, highlighting its diverse mechanism of action against challenging breast cancer subtypes.
PB  - Royal Society of Chemistry
T2  - RSC Medicinal Chemistry
T1  - Exploring the potential of tamoxifen-based copper(II) dichloride in breast cancer therapy
DO  - 10.1039/d3md00344b
ER  - 

@article{
author = "Kazimir, Aleksandr and Schwarze, Benedikt and Lönnecke, Peter and Jelača, Sanja and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Hey-Hawkins, Evamarie",
year = "2023",
abstract = "For decades, tamoxifen-based hormone therapy has effectively addressed oestrogen receptor positive (ER+) luminal A breast cancer. Nonetheless, the emergence of tamoxifen resistance required innovative
approaches, leading to hybrid metallodrugs with several therapeutic effects besides the inhibition of oestrogen receptor α (ERα). Drawing inspiration from tamoxifen metabolite structures (4-hydroxytamoxifen
and 4,4′-dihyroxytamoxifen), a phenyl ring was replaced by a bidentate 2,2′-bipyridine donor moiety to give
4-[1,1-bis(4-methoxyphenyl)but-1-en-2-yl]-2,2′-bipyridine (L), enabling coordination of bioactive transition
metal compounds such as copper(II) dichloride, yielding [CuCl(μ-Cl)(L-κ2N,N′)]2 (1). Notably, copper(II)
complex 1 exhibited remarkable activity within the low micromolar concentration range against ER+ human glioblastoma U251, as well as breast carcinomas MDA-MB-361 and MCF-7, surpassing the efficacy of previously reported palladium(II) and platinum(II) dichloride analogs against these cell lines. The pronounced efficacy of complex 1 against triple-negative MDA-MB-231 cells highlights its potential multitherapeutic approach, evident through induction of apoptosis and antioxidant activity. This study evaluates the potential of copper–tamoxifen hybrid complex 1 as a potent therapeutic candidate, highlighting its diverse mechanism of action against challenging breast cancer subtypes.",
publisher = "Royal Society of Chemistry",
journal = "RSC Medicinal Chemistry",
title = "Exploring the potential of tamoxifen-based copper(II) dichloride in breast cancer therapy",
doi = "10.1039/d3md00344b"
}

Kazimir, A., Schwarze, B., Lönnecke, P., Jelača, S., Mijatović, S., Maksimović-Ivanić, D.,& Hey-Hawkins, E.. (2023). Exploring the potential of tamoxifen-based copper(II) dichloride in breast cancer therapy. in RSC Medicinal Chemistry
Royal Society of Chemistry..
https://doi.org/10.1039/d3md00344b

Kazimir A, Schwarze B, Lönnecke P, Jelača S, Mijatović S, Maksimović-Ivanić D, Hey-Hawkins E. Exploring the potential of tamoxifen-based copper(II) dichloride in breast cancer therapy. in RSC Medicinal Chemistry. 2023;.
doi:10.1039/d3md00344b .

Kazimir, Aleksandr, Schwarze, Benedikt, Lönnecke, Peter, Jelača, Sanja, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Hey-Hawkins, Evamarie, "Exploring the potential of tamoxifen-based copper(II) dichloride in breast cancer therapy" in RSC Medicinal Chemistry (2023),
https://doi.org/10.1039/d3md00344b . .

TY  - JOUR
AU  - Kazimir, Aleksandr
AU  - Schwarze, Benedikt
AU  - Lönnecke, Peter
AU  - Jelača, Sanja
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Hey-Hawkins, Evamarie
PY  - 2023
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5469
AB  - The luminal A-subtype of breast cancer, where the oestrogen receptor α (ERα) is overexpressed, is the most frequent one. The prodrug tamoxifen (1) is the clinically used agent, inhibiting the ERα activity via the formation of several active metabolites, such as 4-hydroxytamoxifen (2) or 4,4′-dihydroxytamoxifen (3). In this study, we present the tamoxifen derivative 4-[1,1-bis(4-methoxyphenyl)but-1-en-2-yl]-2,2′-bipyridine (4), which was combined with platinum or palladium dichloride, the former a well-known scaffold in anticancer treatment, to give [PtCl2(4-κ2N,N′)] (5) or [PdCl2(4-κ2N,N′] (6). To prevent fast exchange of weakly coordinating chlorido ligands in aqueous solution, a bulky, highly stable and hydrophobic nido-carborate(−2) ([C2B9H11]2−) was incorporated. The resulting complexes [3-(4-κ2N,N′)-3,1,2-PtC2B9H11] (7) and [3-(4-κ2N,N′)-3,1,2-PdC2B9H11] (8) exhibit a dramatic change in electronic and biological properties compared to 5 and 6. Thus, 8 is highly selective for triple-negative MDA-MB-231 cells (IC50 = 3.7 μM, MTT test), while 7 is completely inactive against this cell line. The observed cytotoxicity of compounds 4–6 and 8 against this triple-negative cell line suggests off-target mechanisms rather than only ERα inhibition, for which these compounds were originally designed. Spectroscopic properties and electronic structures of the metal complexes were investigated for possible explanations of the biological activities.
PB  - Basel: MDPI
T2  - Pharmaceutics
T1  - Metallodrugs against Breast Cancer: Combining the Tamoxifen Vector with Platinum(II) and Palladium(II) Complexes
IS  - 2
VL  - 15
DO  - 10.3390/pharmaceutics15020682
SP  - 682
ER  - 

@article{
author = "Kazimir, Aleksandr and Schwarze, Benedikt and Lönnecke, Peter and Jelača, Sanja and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Hey-Hawkins, Evamarie",
year = "2023",
abstract = "The luminal A-subtype of breast cancer, where the oestrogen receptor α (ERα) is overexpressed, is the most frequent one. The prodrug tamoxifen (1) is the clinically used agent, inhibiting the ERα activity via the formation of several active metabolites, such as 4-hydroxytamoxifen (2) or 4,4′-dihydroxytamoxifen (3). In this study, we present the tamoxifen derivative 4-[1,1-bis(4-methoxyphenyl)but-1-en-2-yl]-2,2′-bipyridine (4), which was combined with platinum or palladium dichloride, the former a well-known scaffold in anticancer treatment, to give [PtCl2(4-κ2N,N′)] (5) or [PdCl2(4-κ2N,N′] (6). To prevent fast exchange of weakly coordinating chlorido ligands in aqueous solution, a bulky, highly stable and hydrophobic nido-carborate(−2) ([C2B9H11]2−) was incorporated. The resulting complexes [3-(4-κ2N,N′)-3,1,2-PtC2B9H11] (7) and [3-(4-κ2N,N′)-3,1,2-PdC2B9H11] (8) exhibit a dramatic change in electronic and biological properties compared to 5 and 6. Thus, 8 is highly selective for triple-negative MDA-MB-231 cells (IC50 = 3.7 μM, MTT test), while 7 is completely inactive against this cell line. The observed cytotoxicity of compounds 4–6 and 8 against this triple-negative cell line suggests off-target mechanisms rather than only ERα inhibition, for which these compounds were originally designed. Spectroscopic properties and electronic structures of the metal complexes were investigated for possible explanations of the biological activities.",
publisher = "Basel: MDPI",
journal = "Pharmaceutics",
title = "Metallodrugs against Breast Cancer: Combining the Tamoxifen Vector with Platinum(II) and Palladium(II) Complexes",
number = "2",
volume = "15",
doi = "10.3390/pharmaceutics15020682",
pages = "682"
}

Kazimir, A., Schwarze, B., Lönnecke, P., Jelača, S., Mijatović, S., Maksimović-Ivanić, D.,& Hey-Hawkins, E.. (2023). Metallodrugs against Breast Cancer: Combining the Tamoxifen Vector with Platinum(II) and Palladium(II) Complexes. in Pharmaceutics
Basel: MDPI., 15(2), 682.
https://doi.org/10.3390/pharmaceutics15020682

Kazimir A, Schwarze B, Lönnecke P, Jelača S, Mijatović S, Maksimović-Ivanić D, Hey-Hawkins E. Metallodrugs against Breast Cancer: Combining the Tamoxifen Vector with Platinum(II) and Palladium(II) Complexes. in Pharmaceutics. 2023;15(2):682.
doi:10.3390/pharmaceutics15020682 .

Kazimir, Aleksandr, Schwarze, Benedikt, Lönnecke, Peter, Jelača, Sanja, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Hey-Hawkins, Evamarie, "Metallodrugs against Breast Cancer: Combining the Tamoxifen Vector with Platinum(II) and Palladium(II) Complexes" in Pharmaceutics, 15, no. 2 (2023):682,
https://doi.org/10.3390/pharmaceutics15020682 . .

TY  - CONF
AU  - Kazimir, Aleksandr
AU  - Schwarze, Benedikt
AU  - Jelača, Sanja
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Hey-Hawkins, Evamarie
PY  - 2022
UR  - https://eurobic16.sciencesconf.org/
UR  - http://radar.ibiss.bg.ac.rs/handle/123456789/5318
AB  - Tamoxifen (Scheme 1, 1) is historically well known for its successful application in the therapy of
the oestrogen receptor positive (ERα+) breast cancer.1
In this study, we combine a tamoxifenbased ligand2
(Scheme 1, 3) with transition metal complex moieties of platinum(II), palladium(II),
copper(II), and nickel(II)3
containing chlorides (Scheme 1, 4-6) or a bulky, hydrophobic and stable
nido-dicarborate ligand (Scheme 1, 7-9). We investigated the anticancer activity of the
compounds 2-9 in in vitro cell assays. The incorporation of a 2,2’-bipyridine unit into a tamoxifen-inspired structure 3 increases the
cytotoxic activity compared to compound 2 against several cell lines including ERα+ human
glioblastoma (U251), breast adenocarcinoma (MCF-7, MDA-MB-361) and triple negative (ERα−)
MDA-MB-231. The formation of PtII and PdII chloride complexes (4 and 5) insignificantly improve
the activity compared to ligand 3. The ability of the CuII chloride moiety for ligand exchange in
solution explains the significant rise of the cytotoxicity of 6 compared to 4 and 5. However, the
incorporation of a nido-carborate dianion into Pt and Ni complexes (7 and 9) neutralised on
average their toxicity towards all studied cell lines, except compound 8 which was active against
U251 and MDA-MB-231. The observed cytotoxicity data of compounds 3-6 and 8 against MDAMB-231 (ERα−) suggest other off-target mechanisms rather than only ERα inhibition which is
usual for metallodrugs.
PB  - Society of Biological Inorganic Chemistry
C3  - 16th European Biological Inorganic Chemistry Conference: EuroBIC-16; 2022 Jul 17-21; Grenoble, France
T1  - Tamoxifen-based compounds in the breast cancer therapy
SP  - BI31
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_5318
ER  - 

@conference{
author = "Kazimir, Aleksandr and Schwarze, Benedikt and Jelača, Sanja and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Hey-Hawkins, Evamarie",
year = "2022",
abstract = "Tamoxifen (Scheme 1, 1) is historically well known for its successful application in the therapy of
the oestrogen receptor positive (ERα+) breast cancer.1
In this study, we combine a tamoxifenbased ligand2
(Scheme 1, 3) with transition metal complex moieties of platinum(II), palladium(II),
copper(II), and nickel(II)3
containing chlorides (Scheme 1, 4-6) or a bulky, hydrophobic and stable
nido-dicarborate ligand (Scheme 1, 7-9). We investigated the anticancer activity of the
compounds 2-9 in in vitro cell assays. The incorporation of a 2,2’-bipyridine unit into a tamoxifen-inspired structure 3 increases the
cytotoxic activity compared to compound 2 against several cell lines including ERα+ human
glioblastoma (U251), breast adenocarcinoma (MCF-7, MDA-MB-361) and triple negative (ERα−)
MDA-MB-231. The formation of PtII and PdII chloride complexes (4 and 5) insignificantly improve
the activity compared to ligand 3. The ability of the CuII chloride moiety for ligand exchange in
solution explains the significant rise of the cytotoxicity of 6 compared to 4 and 5. However, the
incorporation of a nido-carborate dianion into Pt and Ni complexes (7 and 9) neutralised on
average their toxicity towards all studied cell lines, except compound 8 which was active against
U251 and MDA-MB-231. The observed cytotoxicity data of compounds 3-6 and 8 against MDAMB-231 (ERα−) suggest other off-target mechanisms rather than only ERα inhibition which is
usual for metallodrugs.",
publisher = "Society of Biological Inorganic Chemistry",
journal = "16th European Biological Inorganic Chemistry Conference: EuroBIC-16; 2022 Jul 17-21; Grenoble, France",
title = "Tamoxifen-based compounds in the breast cancer therapy",
pages = "BI31",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_5318"
}

Kazimir, A., Schwarze, B., Jelača, S., Mijatović, S., Maksimović-Ivanić, D.,& Hey-Hawkins, E.. (2022). Tamoxifen-based compounds in the breast cancer therapy. in 16th European Biological Inorganic Chemistry Conference: EuroBIC-16; 2022 Jul 17-21; Grenoble, France
Society of Biological Inorganic Chemistry., BI31.
https://hdl.handle.net/21.15107/rcub_ibiss_5318

Kazimir A, Schwarze B, Jelača S, Mijatović S, Maksimović-Ivanić D, Hey-Hawkins E. Tamoxifen-based compounds in the breast cancer therapy. in 16th European Biological Inorganic Chemistry Conference: EuroBIC-16; 2022 Jul 17-21; Grenoble, France. 2022;:BI31.
https://hdl.handle.net/21.15107/rcub_ibiss_5318 .

Kazimir, Aleksandr, Schwarze, Benedikt, Jelača, Sanja, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Hey-Hawkins, Evamarie, "Tamoxifen-based compounds in the breast cancer therapy" in 16th European Biological Inorganic Chemistry Conference: EuroBIC-16; 2022 Jul 17-21; Grenoble, France (2022):BI31,
https://hdl.handle.net/21.15107/rcub_ibiss_5318 .

TY  - JOUR
AU  - Schwarze, Benedikt
AU  - Jelača, Sanja
AU  - Welcke, Linda
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Hey-Hawkins, Evamarie
PY  - 2019
UR  - https://onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.201900554
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3531
AB  - Investigations on the antitumor activity of metallacarboranes are sparse in the literature and limited to a handful of ruthena- and molybdacarboranes. In this study, the molybdacarborane fragment [3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] was combined with a vector molecule, inspired by the well-known drug tamoxifen or 4,4'-dihydroxytamoxifen (TAM-diOH). The molybdacarborane derivative [3,3-{4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine-κ2 N,N'}-3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] (10), as well as the ligand itself 4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine (6) showed cytotoxic activities in the low micromolar range against breast adenocarcinoma (MDA-MB-231, MDA-MB-361 and MCF-7), human glioblastoma (LN-229) and human glioma (U-251) cell lines. In addition, compounds 6 and 10 were found to induce senescence and cytodestructive autophagy, lower ROS/RNS levels, but only the molybdacarborane 10 induced a strong increase of nitric oxide (NO) concentration in the MCF-7 cells.
T2  - ChemMedChem
T1  - 2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes.
IS  - 24
VL  - 14
DO  - 10.1002/cmdc.201900554
SP  - 2075
EP  - 2083
ER  - 

@article{
author = "Schwarze, Benedikt and Jelača, Sanja and Welcke, Linda and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Hey-Hawkins, Evamarie",
year = "2019",
abstract = "Investigations on the antitumor activity of metallacarboranes are sparse in the literature and limited to a handful of ruthena- and molybdacarboranes. In this study, the molybdacarborane fragment [3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] was combined with a vector molecule, inspired by the well-known drug tamoxifen or 4,4'-dihydroxytamoxifen (TAM-diOH). The molybdacarborane derivative [3,3-{4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine-κ2 N,N'}-3-(CO)2 -closo-3,1,2-MoC2 B9 H11 ] (10), as well as the ligand itself 4-[1,1-bis(4-hydroxyphenyl)but-1-en-2-yl]-2,2'-bipyridine (6) showed cytotoxic activities in the low micromolar range against breast adenocarcinoma (MDA-MB-231, MDA-MB-361 and MCF-7), human glioblastoma (LN-229) and human glioma (U-251) cell lines. In addition, compounds 6 and 10 were found to induce senescence and cytodestructive autophagy, lower ROS/RNS levels, but only the molybdacarborane 10 induced a strong increase of nitric oxide (NO) concentration in the MCF-7 cells.",
journal = "ChemMedChem",
title = "2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes.",
number = "24",
volume = "14",
doi = "10.1002/cmdc.201900554",
pages = "2075-2083"
}

Schwarze, B., Jelača, S., Welcke, L., Maksimović-Ivanić, D., Mijatović, S.,& Hey-Hawkins, E.. (2019). 2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes.. in ChemMedChem, 14(24), 2075-2083.
https://doi.org/10.1002/cmdc.201900554

Schwarze B, Jelača S, Welcke L, Maksimović-Ivanić D, Mijatović S, Hey-Hawkins E. 2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes.. in ChemMedChem. 2019;14(24):2075-2083.
doi:10.1002/cmdc.201900554 .

Schwarze, Benedikt, Jelača, Sanja, Welcke, Linda, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Hey-Hawkins, Evamarie, "2,2'-Bipyridine-Modified Tamoxifen: A Versatile Vector for Molybdacarboranes." in ChemMedChem, 14, no. 24 (2019):2075-2083,
https://doi.org/10.1002/cmdc.201900554 . .

TY  - JOUR
AU  - Gozzi, Marta
AU  - Schwarze, Benedikt
AU  - Sárosi, Menyhárt-Botond
AU  - Lönnecke, Peter
AU  - Drača, Dijana
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Hey-Hawkins, Evamarie
PY  - 2017
UR  - http://xlink.rsc.org/?DOI=C7DT02027A
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2858
AB  - Three [(η6-arene)RuC2B9H11] complexes (arene = p-cymene (2), biphenyl (3) and 1-Me-4-COOEt-C6H4 (4)) were synthesised according to modified literature procedures and fully characterised. 2-4 were found to be moderately active against two types of tumour cell lines (HCT116 and MCF7), with IC50 values in the low micromolar range. However, viability of normal, healthy cells (MRC-5 cell line, MLEC and mouse macrophages) was not affected by treatment with 2-4, indicating high selectivity of the metallacarborane complexes towards tumour cell lines, compared to the unselective antitumour agent cisplatin and other potential RuII drugs. Moreover, flow cytometric analysis suggested that 4 induces cell death via a caspase-dependent apoptotic mechanism. DFT calculations of the frontier molecular orbitals showed that the HOMO-LUMO gap in 2-4 is smaller than in the corresponding cyclopentadienyl complexes 2-Cp-4-Cp (e.g. 5.47 (2) vs. 6.31 eV (2-Cp)). In order to assess the stability of 2-4, particularly the ruthenium-dicarbollide bond, energy decomposition analysis (EDA) of 2-4, together with the respective cyclopentadienyl analogues 2-Cp-4-Cp, was performed. EDA suggests that the ruthenium(ii)-dicarbollide bond in the three complexes is mostly ionic and far stronger than the ruthenium(ii)-arene bond.
T2  - Dalton Transactions
T1  - Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines
IS  - 36
VL  - 46
DO  - 10.1039/C7DT02027A
SP  - 12067
EP  - 12080
ER  - 

@article{
author = "Gozzi, Marta and Schwarze, Benedikt and Sárosi, Menyhárt-Botond and Lönnecke, Peter and Drača, Dijana and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Hey-Hawkins, Evamarie",
year = "2017",
abstract = "Three [(η6-arene)RuC2B9H11] complexes (arene = p-cymene (2), biphenyl (3) and 1-Me-4-COOEt-C6H4 (4)) were synthesised according to modified literature procedures and fully characterised. 2-4 were found to be moderately active against two types of tumour cell lines (HCT116 and MCF7), with IC50 values in the low micromolar range. However, viability of normal, healthy cells (MRC-5 cell line, MLEC and mouse macrophages) was not affected by treatment with 2-4, indicating high selectivity of the metallacarborane complexes towards tumour cell lines, compared to the unselective antitumour agent cisplatin and other potential RuII drugs. Moreover, flow cytometric analysis suggested that 4 induces cell death via a caspase-dependent apoptotic mechanism. DFT calculations of the frontier molecular orbitals showed that the HOMO-LUMO gap in 2-4 is smaller than in the corresponding cyclopentadienyl complexes 2-Cp-4-Cp (e.g. 5.47 (2) vs. 6.31 eV (2-Cp)). In order to assess the stability of 2-4, particularly the ruthenium-dicarbollide bond, energy decomposition analysis (EDA) of 2-4, together with the respective cyclopentadienyl analogues 2-Cp-4-Cp, was performed. EDA suggests that the ruthenium(ii)-dicarbollide bond in the three complexes is mostly ionic and far stronger than the ruthenium(ii)-arene bond.",
journal = "Dalton Transactions",
title = "Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines",
number = "36",
volume = "46",
doi = "10.1039/C7DT02027A",
pages = "12067-12080"
}

Gozzi, M., Schwarze, B., Sárosi, M., Lönnecke, P., Drača, D., Maksimović-Ivanić, D., Mijatović, S.,& Hey-Hawkins, E.. (2017). Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines. in Dalton Transactions, 46(36), 12067-12080.
https://doi.org/10.1039/C7DT02027A

Gozzi M, Schwarze B, Sárosi M, Lönnecke P, Drača D, Maksimović-Ivanić D, Mijatović S, Hey-Hawkins E. Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines. in Dalton Transactions. 2017;46(36):12067-12080.
doi:10.1039/C7DT02027A .

Gozzi, Marta, Schwarze, Benedikt, Sárosi, Menyhárt-Botond, Lönnecke, Peter, Drača, Dijana, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Hey-Hawkins, Evamarie, "Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines" in Dalton Transactions, 46, no. 36 (2017):12067-12080,
https://doi.org/10.1039/C7DT02027A . .

TY  - GEN
AU  - Gozzi, Marta
AU  - Schwarze, Benedikt
AU  - Sárosi, Menyhárt-Botond
AU  - Lönnecke, Peter
AU  - Drača, Dijana
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Hey-Hawkins, Evamarie
PY  - 2017
UR  - http://xlink.rsc.org/?DOI=C7DT02027A
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2848
AB  - Three [(η6-arene)RuC2B9H11] complexes (arene = p-cymene (2), biphenyl (3) and 1-Me-4-COOEt-C6H4 (4)) were synthesised according to modified literature procedures and fully characterised. 2–4 were found to be moderately active against two types of tumour cell lines (HCT116 and MCF7), with IC50 values in the low micromolar range. However, viability of normal, healthy cells (MRC-5 cell line, MLEC and mouse macrophages) was not affected by treatment with 2–4, indicating high selectivity of the metallacarborane complexes towards tumour cell lines, compared to the unselective antitumour agent cisplatin and other potential RuII drugs. Moreover, flow cytometric analysis suggested that 4 induces cell death via a caspase-dependent apoptotic mechanism. DFT calculations of the frontier molecular orbitals showed that the HOMO–LUMO gap in 2–4 is smaller than in the corresponding cyclopentadienyl complexes 2-Cp–4-Cp (e.g. 5.47 (2) vs. 6.31 eV (2-Cp)). In order to assess the stability of 2–4, particularly the ruthenium–dicarbollide bond, energy decomposition analysis (EDA) of 2–4, together with the respective cyclopentadienyl analogues 2-Cp–4-Cp, was performed. EDA suggests that the ruthenium(II)–dicarbollide bond in the three complexes is mostly ionic and far stronger than the ruthenium(II)–arene bond.
PB  - The Royal Society of Chemistry
T2  - Dalton Transactions
T1  - Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines
DO  - 10.1039/C7DT02027A
ER  - 

@misc{
author = "Gozzi, Marta and Schwarze, Benedikt and Sárosi, Menyhárt-Botond and Lönnecke, Peter and Drača, Dijana and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Hey-Hawkins, Evamarie",
year = "2017",
abstract = "Three [(η6-arene)RuC2B9H11] complexes (arene = p-cymene (2), biphenyl (3) and 1-Me-4-COOEt-C6H4 (4)) were synthesised according to modified literature procedures and fully characterised. 2–4 were found to be moderately active against two types of tumour cell lines (HCT116 and MCF7), with IC50 values in the low micromolar range. However, viability of normal, healthy cells (MRC-5 cell line, MLEC and mouse macrophages) was not affected by treatment with 2–4, indicating high selectivity of the metallacarborane complexes towards tumour cell lines, compared to the unselective antitumour agent cisplatin and other potential RuII drugs. Moreover, flow cytometric analysis suggested that 4 induces cell death via a caspase-dependent apoptotic mechanism. DFT calculations of the frontier molecular orbitals showed that the HOMO–LUMO gap in 2–4 is smaller than in the corresponding cyclopentadienyl complexes 2-Cp–4-Cp (e.g. 5.47 (2) vs. 6.31 eV (2-Cp)). In order to assess the stability of 2–4, particularly the ruthenium–dicarbollide bond, energy decomposition analysis (EDA) of 2–4, together with the respective cyclopentadienyl analogues 2-Cp–4-Cp, was performed. EDA suggests that the ruthenium(II)–dicarbollide bond in the three complexes is mostly ionic and far stronger than the ruthenium(II)–arene bond.",
publisher = "The Royal Society of Chemistry",
journal = "Dalton Transactions",
title = "Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines",
doi = "10.1039/C7DT02027A"
}

Gozzi, M., Schwarze, B., Sárosi, M., Lönnecke, P., Drača, D., Maksimović-Ivanić, D., Mijatović, S.,& Hey-Hawkins, E.. (2017). Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines. in Dalton Transactions
The Royal Society of Chemistry..
https://doi.org/10.1039/C7DT02027A

Gozzi M, Schwarze B, Sárosi M, Lönnecke P, Drača D, Maksimović-Ivanić D, Mijatović S, Hey-Hawkins E. Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines. in Dalton Transactions. 2017;.
doi:10.1039/C7DT02027A .

Gozzi, Marta, Schwarze, Benedikt, Sárosi, Menyhárt-Botond, Lönnecke, Peter, Drača, Dijana, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Hey-Hawkins, Evamarie, "Antiproliferative activity of (η 6 -arene)ruthenacarborane sandwich complexes against HCT116 and MCF7 cell lines" in Dalton Transactions (2017),
https://doi.org/10.1039/C7DT02027A . .